This publication out today in ACS Nano, VAR2 Pharma co-authors report proof-of concept for how oncofetal chondroitin sulfate on cancer cells can be targeted by nanoparticle-formulations of red blood cells. This system builds on a natural binding-module mediating attachment of malaria-infected red blood cells to oncofetal chondroitin sulfate presented in the placental and malignant tissue […]
